Everything tagged "dividend" across research, earnings, and macro.
108 articles
ConocoPhillips looks attractive for balanced investors thanks to a low-cost resource base, disciplined capital returns, and a visible free cash flow improvement path through 2029. The main risk remains commodity-price volatility, but the stock appears undervalued relative to its cash generation and project pipeline.
STMicroelectronics looks like a trough-year recovery story: 2025 results were weak, but a strong balance sheet, improving inventory visibility, and growth in automotive, industrial, and optical connectivity support a medium-term rebound.
Chevron is executing well operationally, with 2025 production up 12% and a stronger portfolio after Hess, but the stock still faces a valuation and oil-price overhang. The report rates CVX a Buy on weakness for medium-term investors.
Banco Santander is delivering record profits, strong capital returns, and improving efficiency across a diversified global banking platform. The stock looks like a quality rerating candidate rather than a deep-value turnaround.
Shell combines scale, LNG leadership, and strong cash generation with disciplined buybacks and dividends. The report sees a constructive setup for moderate-risk investors despite cyclical exposure and weakness in chemicals.
Exxon Mobil combines scale, strong cash generation, and visible production growth from Guyana, the Permian, and LNG. The stock looks like a solid Buy for investors seeking quality energy exposure, though it appears close to fair value rather than deeply discounted.
HDFC Bank ADR looks like a high-quality compounder with strong capital, best-in-class credit discipline, and a post-merger growth reset. The stock is not cheap, but steady deposit and loan growth could support attractive medium-term compounding.
State Street looks like a solid medium-term Buy as record scale, improving fee mix, and operating leverage support earnings growth. The stock still trades at a reasonable multiple despite stronger revenue, margin, and capital-return trends.
Charles Schwab is a scaled wealth and brokerage platform with strong client asset growth, improving earnings momentum, and multiple ways to monetize its franchise. The stock looks attractive for moderate-risk investors seeking quality growth at a fair price.
Abbott Laboratories is a diversified healthcare compounder with improving growth across medical devices, diagnostics, nutrition, and emerging-market pharmaceuticals. The stock looks high quality but fairly valued, making it more attractive on pullbacks than at current levels.
Travelers is a high-quality property and casualty insurer with strong underwriting, rising investment income, and disciplined capital returns. The stock looks solid, but much of the good news already appears priced in.
U.S. Bancorp looks like a high-quality super-regional bank with improving earnings power, a strong fee mix, and a reasonable valuation. The stock appears positioned for steady compounding rather than a speculative turnaround.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator